Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$153.56 USD
+0.72 (0.47%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.56 USD
+0.72 (0.47%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
Zacks News
Quest Diagnostics (DGX) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics (DGX) Q3 Earnings Surpass, View Strong
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to accelerate volume growth in Q3.
Will New Alliances Aid Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
LabCorp (LH) Names Two Leaders for Major Business Wings
by Zacks Equity Research
Managenment believes that under Schechter's term with Paul and John's crucial support, LabCorp (LH) looks well-positioned to grow and thrive in times ahead.
LabCorp to Expand Hematology Suite With Sysmex America Deal
by Zacks Equity Research
LabCorp (LH) will get to use Sysmex' advanced XN-9100 system, which is a scalable, modular automation system.
Here's Why You Should Hold on to Quest Diagnostics Stock Now
by Zacks Equity Research
Investor confidence is high on Quest Diagnostics (DGX) stock, thanks to solid prospects.
DGX vs. ADUS: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. ADUS: Which Stock Is the Better Value Option?
Is Quest Diagnostics (DGX) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cybersecurity a Top Priority for Healthcare: 3 Stocks to Watch
by Sreyoshi Mukherjee
As cybersecurity is the need of the hour for U.S. healthcare companies, let's keep an eye on three stocks.
All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy
by Zacks Equity Research
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Quest Diagnostics' New Acquisitions and Pacts Aid Growth
by Zacks Equity Research
Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.
Bright Near-Term Outlook for Medical Info Systems Industry
by Sreyoshi Mukherjee
Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.
Why Is Quest Diagnostics (DGX) Down 0.2% Since Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Pick Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Outlook for Outpatient and Home Healthcare Industry Looks Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.
DGX vs. LHCG: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. LHCG: Which Stock Is the Better Value Option?
Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.
Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 2.37% and 0.51%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.
Earnings Preview: Quest Diagnostics (DGX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Women Health a Top Priority Now: 3 Stocks to Watch
by Sreyoshi Mukherjee
Women's healthcare gains global importance, investors might want to keep an eye on these stocks.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Should Invest in Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Quest Diagnostics (DGX) is boosting investors' optimism, courtesy of consistent positive results.
LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space
by Zacks Equity Research
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?